Direct Monitoring of the Strand Passage Reaction of DNA Topoisomerase II Triggers Checkpoint Activation
By necessity, the ancient activity of type II topoisomerases co-evolved with the double-helical structure of DNA, at least in organisms with circular genomes. In humans, the strand passage reaction of DNA topoisomerase II (Topo II) is the target of several major classes of cancer drugs which both poison Topo II and activate cell cycle checkpoint controls. It is important to know the cellular effects of molecules that target Topo II, but the mechanisms of checkpoint activation that respond to Topo II dysfunction are not well understood. Here, we provide evidence that a checkpoint mechanism monitors the strand passage reaction of Topo II. In contrast, cells do not become checkpoint arrested in the presence of the aberrant DNA topologies, such as hyper-catenation, that arise in the absence of Topo II activity. An overall reduction in Topo II activity (i.e. slow strand passage cycles) does not activate the checkpoint, but specific defects in the T-segment transit step of the strand passage reaction do induce a cell cycle delay. Furthermore, the cell cycle delay depends on the divergent and catalytically inert C-terminal region of Topo II, indicating that transmission of a checkpoint signal may occur via the C-terminus. Other, well characterized, mitotic checkpoints detect DNA lesions or monitor unattached kinetochores; these defects arise via failures in a variety of cell processes. In contrast, we have described the first example of a distinct category of checkpoint mechanism that monitors the catalytic cycle of a single specific enzyme in order to determine when chromosome segregation can proceed faithfully.
Published in the journal:
. PLoS Genet 9(10): e32767. doi:10.1371/journal.pgen.1003832
Category:
Research Article
doi:
https://doi.org/10.1371/journal.pgen.1003832
Summary
By necessity, the ancient activity of type II topoisomerases co-evolved with the double-helical structure of DNA, at least in organisms with circular genomes. In humans, the strand passage reaction of DNA topoisomerase II (Topo II) is the target of several major classes of cancer drugs which both poison Topo II and activate cell cycle checkpoint controls. It is important to know the cellular effects of molecules that target Topo II, but the mechanisms of checkpoint activation that respond to Topo II dysfunction are not well understood. Here, we provide evidence that a checkpoint mechanism monitors the strand passage reaction of Topo II. In contrast, cells do not become checkpoint arrested in the presence of the aberrant DNA topologies, such as hyper-catenation, that arise in the absence of Topo II activity. An overall reduction in Topo II activity (i.e. slow strand passage cycles) does not activate the checkpoint, but specific defects in the T-segment transit step of the strand passage reaction do induce a cell cycle delay. Furthermore, the cell cycle delay depends on the divergent and catalytically inert C-terminal region of Topo II, indicating that transmission of a checkpoint signal may occur via the C-terminus. Other, well characterized, mitotic checkpoints detect DNA lesions or monitor unattached kinetochores; these defects arise via failures in a variety of cell processes. In contrast, we have described the first example of a distinct category of checkpoint mechanism that monitors the catalytic cycle of a single specific enzyme in order to determine when chromosome segregation can proceed faithfully.
Introduction
Type II topoisomerases make a transient double-strand break in one DNA helix (the Gate-segment), pass a second helix through the break (the Transported-segment), then re-ligate the G-segment (Figure 1) [1]–[3]. This Strand Passage Reaction (SPR) has been widely studied because it is the target of important classes of anti-microbial and anti-cancer drugs, as well as a large array of natural products [4], [5]. Upon chemical inhibition of Topo II, cellular checkpoint response pathways are activated that attempt to delay the cell cycle and thus prevent chromosome mis-segregation and/or cell death. Firstly, the DNA damage checkpoint response [4] is activated by a class of Topo II inhibitor, so-called Topo II “poisons”, that trap Topo II-DNA cleavage complexes. When locked in this conformation, the ternary DNA-protein-drug complex can deteriorate to produce DNA breaks that are recognized by the DNA damage checkpoint machinery. This cellular response has been extensively studied and its induction is not specific to DNA damage that results from Topo II poisons. A second class, referred to as Topo II catalytic inhibitors, including the bisdioxopiperazines, do not induce enzyme-mediated DNA cleavage, but block the overall catalytic activity of Topo II by trapping the enzyme in a state in which the N-terminal gate is closed (see Figure 1). These inhibitors activate alternative checkpoint controls that arrest the cell cycle [6]–[10], but the cell cycle control mechanisms that are employed are not well understood [6] and it is of particular interest to determine how checkpoint signaling occurs in the absence of DNA cleavage. A current subject of much controversy is whether the checkpoint detects dysfunctional Topo II directly or if cells utilize other well-characterized mechanisms, for example the spindle assembly checkpoint, to indirectly monitor Topo II activity via topological changes in chromosomal DNA.
Using the bisdioxopiperazine ICRF-193 to activate checkpoint signaling in human cells, one study has demonstrated binding of the DNA damage checkpoint signaling protein MDC1 to the C-terminus of Topo II, which thus induces cell cycle arrest in G2-phase [11]. Because the divergent C-terminal region is dispensable for the strand passage reaction of the enzyme, one explanation of these data is that inefficient or arrested catalysis is structurally transferred to the C-terminus where signaling complexes then assemble. However, the bisdioxopiperazines can bind to Topo II enzymes that are not associated with DNA [12] and are therefore not engaged in the strand passage reaction. Thus, it has not been determined whether checkpoint controls have the ability to directly assess the strand passage reaction.
A further complication is that a mitotic (as opposed to a G2-phase) checkpoint response is also activated by ICRF-193 in human cells and in yeast cells, Topo II (top2) mutants arrest mitotic progression via Mad2-dependent inhibition of anaphase onset [9], [13]. Mad2 is a spindle checkpoint protein that prevents chromatid disjunction when chromosomes are not properly bioriented on the mitotic spindle. The well-understood mechanisms that activate Mad2 can be initiated by aberrant tension at kinetochores [14], [15]. This indicates that Topo II (named Top2, in yeast) dysfunction in yeast mutants, or in mitotic human cells treated with ICRF-193, may be sensed indirectly, via structural changes at the centromere regions of chromosomes. This is an attractive hypothesis given that Topo II is concentrated at the centromere regions [16]–[18], that the strand passage reaction alters DNA topology [19], [20], and that some yeast top2 mutant strains have altered centric chromatin structure [21]. It therefore remains unknown whether checkpoints that respond to Topo II inhibition involve novel signaling mechanisms or simply activate the already well-understood mitotic checkpoint pathways.
Here we demonstrate that, in yeast, the strand passage reaction of Topo II is directly monitored and that checkpoint signaling originates from the defective homodimeric enzyme at specific conformational states within the strand passage reaction. Checkpoint activation under these defined conditions requires the C-terminal region of the enzyme, supporting the hypothesis that a structural transference of defective catalysis to the enzymatically inert C-terminus allows checkpoint signaling. This is the first example of a checkpoint mechanism that directly monitors the catalytic cycle of a single enzyme.
Results/Discussion
Yeast top2 Mutant Alleles Activate a Non-Conventional Mad2-Dependent Checkpoint
We previously studied yeast strains harboring the top2-B44 hypomorphic allele of Topo II which induces a Mad2-dependent cell cycle delay in G2 (equivalent to the metaphase stage of mitosis in mammalian cells). This checkpoint was not activated due to the accumulation of DNA stand breaks [13]. Correspondingly, the DNA damage checkpoint was not activated and the major kinases involved in the DNA damage response (Rad53 and Mec1) were dispensable for G2 checkpoint activation in top2-B44 cells [13]. In contrast, the spindle checkpoint protein Mad2 was essential for G2 checkpoint activation, suggesting that aberrant chromosome structure, especially kinetochore structure, may be defective under conditions of limited Topo II activity. To test this hypothesis we examined chromosome attachment to the mitotic spindle apparatus in top2-B44 cells and surprisingly found no evidence in favor of aberrant attachment of kinetochores to the mitotic spindle [13]. Intriguingly, the checkpoint delay was at least partially independent of other effectors of the spindle checkpoint response; Pds1 and Bub3 [13].
To understand the mechanism of checkpoint activation in top2-B44 cells, we first examined if reduced Topo II activity affected chromosome condensation. We employed an assay characterized previously in which chromosome compaction is monitored using marked chromosomal loci on the long arm of chromosome IV in yeast [22]. This analysis revealed that temporally concomitant with checkpoint activation in top2-B44 cells, there was no defect in chromosome linear compaction (Figure S1). In fact, chromosome condensation occurred just as efficiently as in wild type cells.
In the Absence of Top2, DNA Topology Defects Do Not Activate the Mad2-Dependent G2 Checkpoint
Because a wide variety of assays failed to provide any evidence that aberrant DNA topology or DNA breaks in top2-B44 cells were the cause of G2 checkpoint activation (i.e. indirect consequences of perturbed Topo II activity), we next considered the possibility that cells may directly monitor the enzyme activity of Topo II. A system was established to control expression and degradation of Top2 in yeast using a degron allele (top2deg) expressed from the MET3 promoter (Figure 2a). Top2deg contains a Ubiquitin-Arg-DHFR fusion which destabilizes folding at high temperature and becomes poly-ubiquitylated by the E3 ligase, Ubr1 [23]. Tight control of top2deg expression and Top2deg degradation was achieved (Figure 2b and Figure S2). After G1 synchronization, Top2deg was abolished to undetectable levels, allowing effects on progression through a subsequent cell cycle in the absence of Top2 to be observed, as previously described [24]. Under such conditions, if cells reached G2 unable to resolve DNA catenations arising during DNA replication, then upon anaphase entry these cells ought to fail to segregate their chromosomes. This was indeed the outcome in ∼90% of cells examined (Figure 2c), indicating that they reached G2 with extensive DNA topological defects arising under conditions of Top2-deficiency. To confirm this conclusion via biochemical means, we asked if top2deg cells grown under the above conditions (i.e. released from G1 after the depletion of Top2) reached G2 with catenated DNA. We isolated genomic DNA from such cells and following separation on CHEF gels, probed resulting Southern blots to detect the endogenous yeast circular 2-micron plasmid (as previously used to assess the catenation state of yeast genomic DNA; see Material and Methods). As a positive control we examined genomic DNA from top2-4 cells grown in parallel under restrictive conditions. In both cases, extensively catenated 2-micron circular DNA was detected, whereas none was observed in samples from either mutant strain grown under permissive conditions or from wild type cells grown at high temperature (Figure 2d). Based on this molecular analysis of DNA catenation and the analysis of chromosome segregation in vivo, we conclude that following depletion of Top2deg in G1, cells progress through the cell cycle with severely limited, if not absent, Top2 activity, resulting in persistent DNA hyper-catenation and failed chromosome segregation.
The presence of DNA hyper-catenation must result in extensive chromosome topological defects, particularly at the centromere regions of chromosomes where Topo II is concentrated in mitosis. It can therefore be predicted that DNA hyper-catenation activates the spindle assembly checkpoint via aberrant centric (centromeric) chromatin. To test this hypothesis, we used two different assays to measure the approximate duration of G2 following depletion of Top2deg in G1 and release of the cells from G1 synchrony. First we used a commonly used “population assay” where samples were taken from the population every 10–20 min and cells categorized into G1, G2 and anaphase morphologies based on mitotic spindle characteristics [24]. This yielded plots that revealed the approximate timing of anaphase spindle elongation relative to spindle assembly, which defines the duration of G2 (Figure 3a–c, Figure S3). Surprisingly, the length of G2 after Top2 depletion was very similar to that in the same strain but carrying an additional copy of wild type TOP2 expressed from its endogenous promoter. Thus, the absence of Top2 did not induce a G2 cell cycle delay.
In a second assay, we studied cell cycle progression in single cells by digital time-lapse imaging (Figure 3d–f). Here, we recorded cells expressing GFP-tagged tubulin, acquiring z-stacks of images at a temporal resolution of 2 min. Except for growth in a micro-fluidic chamber, the experimental conditions of synchrony and Top2 depletion were identical to those used in the population assay. The resulting time-lapse movies were analyzed as follows to determine the average length of G2. First, we identified cells that completed the cell cycle within the duration of each movie. Second, we located the first time point (movie frame) in which two Spindle Pole Bodies (SPBs) could be observed (Figure 3d, second frame) and we then measured SPB diameter in the previous five movie frames to obtain a baseline SPB size. Next, we measured spindle length in all subsequent movie frames until full spindle elongation in anaphase had occurred. Approximate G2 length could then be determined by averaging the time interval from SPB separation to the onset of spindle elongation. We found that variation between cells was minimal as long as at least twenty cells were analyzed per strain. In addition to displaying simple histogram plots of G2 duration, we found that it was informative to plot average spindle length versus time, after the cells analyzed were aligned at the time of SPB separation (Figure 3e). In this manner, spindle lengths were largely very similar at each time point until a fraction of the cells initiated anaphase. Because spindle length differences are large in anaphase and are much larger than the length of the spindle in cells that were still in G2 at such time-points, standard deviation of spindle length became large, indicative of the trend towards anaphase onset among the cells recorded (Figure 3e, right side of the plots). In these single-cell assays, not unexpectedly, the kinetics of cell cycle progression was elongated due to growth within a static chamber, versus vigorous shaking used in the population assays. Nevertheless, these studies also revealed that the duration of G2 is very similar in cells depleted of Top2deg versus cells producing Top2 at endogenous levels (Figure 3e,f).
We conclude that anaphase onset was not delayed when cells were allowed to progress from G1 after depletion of Top2 (Figure 3a–f, Figure S3). Presumably any centromeric chromatin defects that are a consequence of hyper-DNA catenation are not sufficient to activate a pre-anaphase checkpoint, including the spindle checkpoint. This conclusion is consistent with a previous study indicating that lack of Top2 in yeast does not delay mitotic progression [25] and studies in human cells in which checkpoint activation was not observed upon depletion of Topo II [10].
Top2-B44 Activates a Mad2-Dependent G2 Delay when Associated with DNA
Because Top2 depletion did not activate checkpoint signaling but certain top2 alleles are known to induce a Mad2-dependent cell cycle delay [13], we asked if a checkpoint response can be initiated in the top2deg strain after introduction of the top2-B44 allele. When Top2deg was depleted in G1 and Top2-B44 was expressed at endogenous levels (Figure 4a), population analysis revealed that anaphase initiation in the subsequent cell cycle was indeed delayed, indicating checkpoint activation (Figure 4a, Figure S3). Identical strains, but lacking the MAD2 gene, did not delay before anaphase, confirming that the transient cell cycle arrest was Mad2 checkpoint-dependent. Single-cell assays confirmed these results (Figure 4b,c).
The above experiments demonstrated that hyper-catenated DNA was not sufficient for the induction of cell cycle arrest, but the presence of Top2-B44 protein did trigger checkpoint activation. A possible explanation is that cells can directly detect the aberrant activity of Top2-B44 and respond by initiating checkpoint signaling via Mad2. Similar to the effects of the drug ICRF-193, which can bind to Topo II in the absence of DNA [12], checkpoint activation in top2-B44 cells could be due to the detection of abnormal Top2-B44 protein structure, independent of Top2 activity, or could be a result of direct monitoring of the SPR enzyme cycle. To distinguish between these alternatives, we took advantage of SPR mutants that have been characterized previously in structural/biochemical studies [26]–[32] (see Figure 1) and we performed both population and single-cell assays to confirm our findings. First, we asked whether Top2-B44 not only needs to be physically present in the cell, but also must be bound to DNA in order for checkpoint activation to occur. We introduced a K651A substitution into top2-B44. The conserved residue, K651, is present in a small, flexible linker region between the highly structured TOPRIM and WHD domains of Top2 that form the deep positively charged groove in which the G-segment DNA is housed [27]. Top2K651A has a vastly reduced affinity for DNA [30] and cannot support cell viability (ref. 30 and data not shown). However, the K651A substitution is predicted not to destabilize the overall structure of Top2 [30]. Consistent with this prediction, Top2-B44K651A was stable in vivo suggesting that it is correctly folded (Figure 4a). In the top2deg strain, Top2-B44K651A was present at similar levels to Top2-B44, but did not induce a pre-anaphase delay (Figure 4a–c, Figure S3), indicating that the checkpoint is only activated when Top2-B44 is associated with DNA. A possible explanation is that the checkpoint monitors defective enzymatic cycles of Top2.
Initiation of the SPR Is Required for Checkpoint Activation by Top2-B44
We next asked if initiation of the SPR is required for checkpoint signaling to occur. The catalytic tyrosine of Top2 [29] was substituted with phenylalanine (Top2Y782F), resulting in an enzyme unable to cleave the G-segment DNA and capture a T-segment, though binding to the G-segment, binding of ATP and closure of the N-gate are not affected (Figure 1, Figure 5a). Top2Y782F arrests bound to the G-segment but before the SPR can be initiated [29]. Population and single-cell analysis of top2deg cells expressing Top2Y782F close to endogenous levels revealed a lack of checkpoint delay (Figure 5b–d, Figure S3). Because a previous study reported that over-expression of TOP2Y782F does activate a checkpoint response [25], we asked if this is the case in our strain background using a GAL-TOP2Y782F construct. Indeed, we did observe a G2 delay similar to the previous study, in agreement with the result that over-produced Top2Y782F induces checkpoint activation (Figure 5c,d). We conclude that at least when present at endogenous levels, a Top2 enzyme that binds the G-segment but is trapped within a futile cycle of N-Gate opening and closure does not activate checkpoint signaling. We next substituted Y782 with phenylalanine in the Top2-B44 enzyme (Top2-B44Y782F). Similar to top2deg cells expressing Top2Y782F, this enzyme, expressed near endogenous levels, did not trigger checkpoint activation (Figure 5b–d, Figure S3). We infer that a defective step of the SPR of Top2-B44, subsequent to G-segment cleavage, is required for checkpoint activation, presumably because a downstream step of the SPR enzyme cycle is directly monitored.
Defects in ATP Hydrolysis by Top2 Activate the Mad2-Dependent Checkpoint
Top2Y782F cannot cleave G-segment DNA and as a consequence it cannot adopt the closed-clamp form of the enzyme with a captured T-segment within the closed N-gate; there appears to be insufficient space within the N-terminal orifice of the dimeric enzyme when bounded by an intact G-segment [27]. To ask if T-segment capture and closure of the N-gate must occur for checkpoint activation, we analyzed top2G144I, a mutant that cannot bind ATP/ADP and thus cannot close the N-gate, but can, albeit inefficiently, cleave the G-segment (Figure 6a) [28]. Interestingly the checkpoint was activated by Top2G144I similar to Top2-B44 (Figure 6b,c,i,j and Figure S4). Thus, N-gate closure with a captured T-segment is not required for checkpoint activation.
From biochemical and structural predictions, the Top2G144I mutant ought not to produce frank DNA breaks and activate the DNA damage checkpoint. Indeed, Top2G144I has reduced DNA cleavage activity because T-segment capture is inefficient [28]. Nevertheless, we asked if the activated checkpoint is Mad2 dependent, as is the case for Top2-B44 [13], or dependent on the DNA damage checkpoint kinase Rad53. Double mutants of top2G144I combined with a deletion of MAD2 did not activate the checkpoint (Figure 6d,i,j and Figure S5), whereas double mutants combined with the checkpoint defective rad53-1 allele or a rad53-null allele (rad53Δ) retained checkpoint signaling (Figure 6g, Figure S5 and Figure S9). Consistent with these findings, we failed to detect Rad53 phosphorylation in cells expressing Top2G144I (Figure S9). Therefore, like top2-B44, the top2G144I cells arrest the cell cycle due to the activation of Mad2, and likely do not activate the DNA damage checkpoint. Consistent with these findings for Top2G144I which cannot bind ATP, we observed that Top2E66Q, defective in ATP hydrolysis (Figure 6a) [26], activates the checkpoint in a Mad2-dependent, but Rad53-independent manner (Figure 6b,f,e,h–j, Figure S6 and Figure S9).
A Defect in T-Segment Transit Activates the Mad2-Dependent Checkpoint Independently of Slow ATP Hydrolysis
Top2E66Q and Top2G144I have in common the inability to utilize the energy of ATP hydrolysis and consequently both enzymes transit very slowly through the coupled mechanism that drives the T-segment transport step of the SPR (Figure 1 and Figure 6a) [26], [28]. To ask if perturbed ATP hydrolysis per se, or conformational changes in the enzyme that promote T-segment transport, are monitored by the checkpoint machinery, we examined strains harboring top2L475A/L480P, which encodes an enzyme proficient in ATP hydrolysis, but defective in T-segment transport (Figure 7a) [32]. Strikingly this mutant activated the checkpoint to the same degree as the ATP binding and hydrolysis mutants, again in a Mad2-dependent, Rad53-independent manner, suggesting that the checkpoint is activated by inefficient T-segment transport (Figure 7b–f, Figure S7 and Figure S9).
We then compared these data with other top2 mutants in which the overall rate of the SPR is slow, but that are predicted not to be defective in T-segment transport through the DNA-gate: Top2P824S and Top2G738D (Figure 1) [31]. Neither mutant led to checkpoint activation (Figure 8a–c, Figure S8). Based on the analysis of these mutants, checkpoint activation does not require: (1) DNA strand breaks, (2) a defect in N-gate opening or closure, or (3) a defect in ATP binding or hydrolysis. Furthermore, an overall reduced rate of strand passage is not sufficient for checkpoint activation. The mutants that activate the checkpoint have in common a defect in the T-segment transport step of the SPR, which is associated with specific conformational states of the enzyme (Figure S10).
Top2-B44 Hydrolyzes ATP Slowly
Top2-B44 had not been characterized biochemically, but based on our analysis of the other mutants, we would predict that Top2-B44 is defective in the T-transport step of the SPR. To address this hypothesis, we purified wild type and Top2-B44 enzymes to homogeneity from yeast (see Material and Methods). First, we asked if Top2-B44 has an altered propensity to cleave supercoiled DNA in the presence of the Topo II poison etoposide. This assay can determine whether the enzyme has a propensity to stall with a cut G-segment. This cleavage activity assay (Figure 9a) revealed that Top2-B44 does not display increased DNA breakage in the presence of etoposide, which is consistent with our failure to detect DNA damage in top2-B44 cells [13] (Figure S9) and is consistent with Mad2-dependent checkpoint activation rather than Rad53-dependent checkpoint activation. We then performed relaxation activity time course experiments to determine the rate of relaxation of supercoiled plasmid DNA (Figure 9b). This analysis demonstrated that Top2-B44 relaxes supercoiled DNA more slowly (∼2.5 to 3-fold) than wild type Top2 at 37°C. Most interestingly, however, Top2-B44 had a reduced rate of ATP hydrolysis (Figure 9c), consistent with checkpoint activation resulting from a defect in the T-transport step of the SPR, and consistent with the biochemical defects of Top2G144I, Top2E66Q and Top2L475A/L480P that all activated a Mad2-dependent G2 checkpoint.
The C-Terminus of Top2-B44 Is Required for Mad2-Dependent Checkpoint Activation
Topo II undergoes major conformation changes as part of the SPR, particularly during the step of the enzyme cycle where the T-segment is transported through the holoenzyme [27], [28]. Our data indicate that a specific conformation might be recognized by the checkpoint machinery. In this case, a determinant may exist within the Topo II quaternary structure that participates in checkpoint signaling. This hypothesis stems from the discovery that, in human cells, the checkpoint signaling protein MDC1 binds to the C-terminus of Topo II [11]. We therefore tested the hypothesis that specific top2 mutants activate a Mad2-dependent checkpoint response via the catalytically inert C-terminal region (CTR). Because the CTR (residues 1321 to the C-terminus) is dispensable for the SPR and for cell viability in yeast [33], we could construct strains expressing either wild type TOP2 with a truncated CTR (top2ΔCTR) or top2-B44 with a truncated CTR (top2-B44ΔCTR). Strikingly, we observed that Top2-B44ΔCTR does not activate checkpoint signaling, demonstrating that the CTR is required for Mad2 activation (Figure 10a–c).
The C-terminal regions of eukaryotic Topo II enzymes are divergent, and thus it is not clear whether the CTRs of human and yeast Topo II possess a conserved binding site for checkpoint proteins. Nevertheless, if checkpoint signaling complexes are recruited to the CTR of yeast Top2, then over-production of the CTR in isolation may sequester the relevant factor(s) and perhaps abrogate checkpoint signaling. This was indeed the outcome when the CTR was expressed from the strongly inducible GAL1 promoter in the top2-B44 strain (Figure 10a–c). These experiments therefore provide evidence that specific defects in the SPR transduce to the C-terminal region, resulting in the activation of checkpoint signaling. This could occur via the physical interaction of checkpoint proteins with the CTR, although other explanations of the data remain, such as over-produced CTR having dominant effects on chromatin that interfere with checkpoint signaling.
Top2-B44 Induces G2 Cell Cycle Delay Independently of Ndc10 and without Gross Mad2 Recruitment to Kinetochores
Dissecting the role of the CTR and the molecular basis of Mad2 activation, remain important future goals. We previously found that checkpoint activation in top2-B44 cells does not coincide with a defect in chromosome biorientation, and that some spindle checkpoint proteins (including Bub3 and the spindle checkpoint target, Pds1) are dispensable for the observed G2 delay [13]. Because these data suggested that a non-conventional spindle checkpoint is activated in top2-B44 cells, we asked if the G2 delay requires the kinetochore protein Ndc10. In the absence of Ndc10, although kinetochores lose their structural integrity, cells are able to progress through the cell cycle and complete mitosis [34]. However, since Mad2 activation must occur at kinetochores when the spindle checkpoint is triggered, ndc10 mutant cells cannot arrest prior to anaphase in the presence of microtubule poisons such as nocodazole [34]. We confirmed these data in our strain background in order to determine conditions that efficiently inactivate the temperature sensitive Ndc10-1 protein in conjunction with cell cycle synchrony in G1-phase. Upon release into the cell cycle, such cells failed to arrest in the presence of nocodazole, progressing into a second cell cycle almost as quickly as untreated cells (Figure 11a). Strikingly, however, under identical conditions but in the absence of nocodazole, top2-B44 ndc10-1 cells delayed in G2-phase (Figure 11b). Therefore, checkpoint activation in top2-B44 cells is independent of Ndc10.
The above data led to the prediction that Mad2 becomes activated in top2-B44 cells independently of kinetochores. We therefore asked if Mad2 is recruited to kinetochores upon checkpoint activation in top2-B44 cells. First we expressed Mad2 tagged with three tandem GFP epitopes in wild type cells in order to verify that we could observe re-localization of Mad2 upon activation of the spindle checkpoint. Indeed, as previously reported [35], within 90 minutes of nocodazole treatment, most cells possessed a single discrete focus of Mad2-GFP (Figure 12a, right panel, and data not shown). In the absence of nocodazole, we did not observe discrete foci of Mad2-GFP in either wild type or top2-B44 cells. Rather, Mad2-GFP was either diffusely localized or localized to structures at the periphery of the nucleus (Figure 12a, left panel, Figure 12b and data not shown), consistent with previous studies showing that Mad2 localizes to nuclear pores in the absence of spindle checkpoint activation [35]. To ensure that Mad2-GFP does not localize to discrete foci in top2-B44 cells, we filmed such cells by time-lapse microscopy at 2.5 minute intervals to observe complete cell cycles (Figure 12b, Movie S2). Analysis of more than 50 cells failed to reveal any Mad2-GFP foci in top2-B44 cells. We conclude that Mad2 does not re-localize to kinetochores and that kinetochores are dispensable for checkpoint activation in top2-B44 cells. These findings are consistent with the genetic analyses described above, and suggest a novel mechanism of Mad2-dependent checkpoint activation via Top2-B44.
Concluding Remarks
It will be important to extend the studies presented here to improve our understanding of mammalian mitotic checkpoint controls. It has been known for some time that inhibition of Topo II in human cells induces a G2 checkpoint delay that is dependent on the DNA damage checkpoint kinase ATM [36]. The checkpoint signaling pathway activated in G2 human cells is therefore clearly distinct from the Mad2-dependent checkpoint that becomes activated in yeast top2 mutants. This likely is the case because the yeast cell cycle is organized quite differently from human cells. Since budding yeast cells assembly their mitotic spindles during S-phase and achieve chromosome biorientation (equivalent to mammalian metaphase chromosome alignment) before the completion of DNA synthesis, they do not possess a G2 cell cycle phase that temporally precedes mitosis. As a result there is no true cell cycle transition between G2 and mitosis and thus no opportunity for biochemical regulation at an equivalent stage to the mammalian G2-prophase transition. Perhaps for this reason, budding yeasts seem to rely heavily on regulation of anaphase onset via Mad2 and other mechanisms that control stability and activity of anaphase inhibitors. Nevertheless, an equivalent cell cycle control to the one we have described in yeast does appear to function in human cells. When metaphase human cells are treated with the Topo II inhibitor ICRF-193, a transient cell cycle delay prior to anaphase onset is observed that endures for approximately 45–60 minutes before anaphase is attempted and cells exit mitosis [37]. Little is known about this cellular response, however, and it will be intriguing to determine how similar it may be to the yeast checkpoint. In addition, it should be noted that much higher doses of ICRF-193 have been reported to silence the spindle checkpoint under conditions where cohesin proteins have been depleted, which results in defective tension at kinetochores and thus activates the spindle checkpoint [38]. The mechanistic basis of this phenomenon remains poorly understood and it is not clear how different doses of ICRF-193 can have very different consequences in vivo. However, it is interesting to note that parallels can be drawn between the yeast Top2E66Q mutant and a wild-type enzyme in the presence of ICRF-193, since in both cases ATP can bind to the topoisomerase but cannot be hydrolyzed. The Top2E66Q mutant, which activates the Mad2-dependent checkpoint in yeast, therefore phenocopies a situation where each Topo II holoenzyme is bound to ICRF-193, without there being an excess of the drug. It is clear that a comprehensive understanding of the interplay between mitotic checkpoints and Topo II function will provide important information in terms of the consequences of inhibiting the enzyme in the context of anti-microbial and anti-cancer treatments.
In this study, we have presented evidence that a Topo II responsive checkpoint is activated through a novel mechanism that detects the enzyme cycle rather than a DNA lesion. DNA topology defects, including hyper-catenation, are not sufficient to trigger checkpoint signaling. Rather, the evidence supports a mechanism whereby the checkpoint machinery directly monitors the SPR of Topo II to ensure that sister chromatid separation can occur in anaphase. The data also indicate that the checkpoint is distinct from other checkpoints. Such a mechanism of checkpoint control could have evolved due to the abundance of naturally occurring Topo II inhibitors such as plant secondary metabolites that interrupt the enzyme cycle [4], [5]. The SPR mutants described here may mimic some of the effects of these inhibitors in that they accumulate specific SPR intermediates that may form a structural platform for assembly of a signaling complex. We propose that checkpoint sensor proteins bind to Topo II when blocked or delayed at specific steps in the SPR. If the assembly of signaling complexes at the CTR of Topo II is a conserved mechanism of checkpoint activation across eukaryotes, then the nature of interaction with the Topo II CTR must have diverged since no homolog of the human MDC1 checkpoint protein exists in yeast. Further understanding of such Topo II-checkpoint protein interactions could be clinically valuable because current efforts aim to identify drugs that inhibit Topo II without activating the checkpoint controls that are protective to tumors cells.
Material and Methods
Yeast Strains and Plasmids
The yeast strains used in this study are haploid derivatives of BF264-15 15DU (see Table S2). Yeast strains were modified according to standard yeast genetic approaches [39]. Plasmids were mutagenized by site-directed mutagenesis according to Liu and Naismith [40].
Growth Conditions to Inactivate Top2deg
Step 1: cells were grown to an OD of 2.0–6.0 overnight at 26°C in synthetic raffinose medium lacking methionine and tryptophan (Figure S2). Step 2: for synchrony, cells were diluted to OD 0.2 in rich raffinose medium at 26°C with α factor (concentration varying from 1∶2200 to 1∶3500 of a 1 mg/ml stock). After 1 h, galactose was added to a final concentration of 4% (Step 3). Following another 30 min growth the temperature was raised to 35°C (Step 4). After a further 30 min growth (2 hours total with α factor) α factor was washed off with water that was pre-warmed to 35°C. The cells were released into YPG at 35°C (Step 5).
Determination of G2/M Period
Population Assays
G2/M period was determined as previously described [13], [24]. Briefly, at each time point and for each strain, at least 100 cells were scored for spindle and budding morphology. The G2/M cell cycle interval was determined by plotting cell cycle categories against time. G2/M was defined as the period after 20% of cells had formed a G2 spindle until 20% of cells formed an anaphase spindle. Each experimental strain was analyzed a minimum of three times. The data in Figure S3, S4, S5, S7, S7, S8 are aligned relative to bud emergence since this signals cell cycle entry and is the variable parameter of cell cycle progression following release from G1 synchrony [13]. For statistical analysis, values for G2/M from the yeast cell cycle analyses were analyzed using One-Way Anova, using the Tukey HSD post-hoc analysis (significance p = 0.05). For values see Table S1.
Single-cell Assays
Following Top2deg deletion and G1 synchrony (as performed for the population assays), strains were grown in a microfluidic chamber housed on a DeltaVision microscope system with defined environmental conditions (humidified at 34°C). Z-stack images were captured at 2 min. intervals. ImageJ (Fiji) was used to measure spindle lengths and average spindle length (+/− s.d.) versus time was plotted with each cell aligned on the x-axis at the first time point in which spindle pole separation could be observed. For histogram plots of the average duration of G2, the interval between spindle pole body separation and anaphase onset was calculated (+/− s.e.). Between 20 and 40 single cells were analyzed for each strain.
Microscopy
Spindle morphologies were visualized using TUB1-GFP [41] as described previously [24]. Nuclear morphologies were visualized using a method from Juan Martinez (Purdue University). Cells were grown under the conditions specified previously and were collected (500 µl) by centrifugation. The resulting pellet was washed once with 1 ml 1× PBS, resuspended in 1.4 ml of filter-sterilized 4% p-formaldehyde solution (4% p-formaldehyde, 3.5% sucrose in water), and incubated for 20 min at room temperature. Cells were then centrifuged at 3000 g and the pellet was washed with 1 ml wash buffer (1.2 M sorbitol, 100 mM potassium phosphate, pH 7.5). Cells were resuspended in 1 ml 1× PBS containing 5 µl of 1 mg/ml DAPI solution and incubated at room temperature for 3 min in the dark. Cells were washed once with 1× PBS and resuspended in the remaining 1× PBS after decanting. Anaphase cells were identified based on spindle morphology and were scored for separated or un-separated nuclei. During a normal mitosis, anaphase cells go through an intermediate stage where the nuclei are stretched, but have not separated completely (this accounts for the low percentage of anaphase cells in wild-type with un-separated nuclei).
Western Blots
Proteins were extracted by collecting 15 mls of cells and resuspending in 1 mL 0.25 M NaOH and 1% BME solution. Resuspensions were placed on ice for 10 min. 160 µl of 50% TCA was added, the solution inverted, and placed on ice for 10 min. The extracts were then pelleted at 14,000 g for 10 min at 4°C. Supernatant was decanted and the pellet resuspended in 1 mL of ice-cold acetone. Extracts were pelleted again and supernatant decanted. The extract was dried for 3 min at 55°C. The dried extract was resuspended in 100 µl of 2× protein-loading buffer and neutralized with 5 µl of 1 M Tris base. Western blots were performed using the following antibodies: 1∶1000 dilution of anti-Top2 (TopoGen), 1∶6000 dilution of anti-Flag (Pierce) and a 1∶2500 dilution of anti-GFP (Clontech). Secondary antibody, HRP-conjugated goat anti-rabbit (Pierce) was used at 1∶5000 and HRP-conjugated goat anti-mouse IgG (Invitrogen) was used at 1∶5000.
CHEF Gels and Southern Blotting
Preparation of yeast cell agarose plugs for CHEF gel electrophoresis was performed as preciously described [42] and were run on a CHEF DRIII electrophoresis system (Bio-Rad) at 11°C, 60–120 sec switch for 18 hours at 6 V/cm with 120° angle. Southern blots were probed to detect catenated 2-micron circle DNA as previously described [43].
Purification and Biochemical Analysis of Top2-B44
Wild type Top2 and Top2-B44 were purified after over-expression in yeast as previously described [44]. Top2 reactions were carried out as described [44] using supercoiled pBR322 to monitor ATP-dependent relaxation and cleavage activity. ATPase assays were performed as described by Osheroff et al. [45]. Reaction mixtures contained 45 nM yeast topoisomerase II, 5 nM negatively supercoiled pBR322 DNA, and 1 mM [γ-32P] ATP in a total of 40 µl of relaxation buffer. Mixtures were incubated at 28°C and 37°C, and 2 µl samples were removed at time intervals up to 15 min and spotted on polyethyleneimine-impregnated thin layer cellulose chromatography plates (EMD Chemicals). Plates were developed by chromatography in freshly made 400 mM NH4HCO3 and analyzed using a Bio-Rad molecular imager FX. ATP hydrolysis was monitored by the release of free phosphate.
Supporting Information
Zdroje
1. BrownPO, CozzarelliNR (1979) A sign inversion mechanism for enzymatic supercoiling of DNA. Science 206 (4422) 1081–1083.
2. LiuLF, LiuCC, AlbertsBM (1979) T4 DNA topoisomerase: a new ATP-dependent enzyme essential for initiation of T4 bacteriophage DNA replication. Nature 281 (5731) 456–461.
3. WangJC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3 (6) 430–440.
4. NitissJL (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9 (5) 338–350.
5. DeweeseJE, OsheroffN (2009) The DNA Cleavage Reaction of Topoisomerase II: Wolf in Sheep's Clothing. Nucleic Acids Res (37) 738–748.
6. DownesCS, ClarkeDJ, MullingerAM, Giménez-AbiánJF, CreightonAM, et al. (1994) A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells. Nature 372 (6505) 467–470.
7. DemingPB, CistulliCA, ZhaoH, GravesPR, Piwnica-WormsH, et al. (2001) The human decatenation checkpoint. Proc Natl Acad Sci U S A 98 (21) 12044–12049.
8. DemingPB, FloresKG, DownesCS, PaulesRS, KaufmannWK (2002) ATR enforces the topoisomerase II-dependent G2 checkpoint through inhibition of Plk1 kinase. J Biol Chem 277 (39) 36832–36838.
9. SkoufiasDA, LacroixFB, AndreassenPR, WilsonL, MargolisRL (2004) Inhibition of DNA decatenation, but not DNA damage, arrests cells at metaphase. Mol Cell 15 (6) 977–990.
10. BowerJJ, KaracaGF, ZhouY, SimpsonDA, Cordeiro-StoneM, et al. (2010) Topoisomerase IIalpha maintains genomic stability through decatenation G(2) checkpoint signaling. Oncogene 29 (34) 4787–4799.
11. LuoK, YuanJ, ChenJ, LouZ (2009) Topoisomerase IIalpha controls the decatenation checkpoint. Nat Cell Biol 11 (2) 204–210.
12. RocaJ, IshidaR, BergerJM, AndohT, WangJC (1994) Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci U S A 91 (5) 1781–1785.
13. AndrewsCA, VasAC, MeierB, Gimenez-AbianJF, Diaz-MartinezLA, et al. (2006) A mitotic topoisomerase II checkpoint in budding yeast is required for genome stability but acts independently of Pds1/securin. Genes Dev 20 (9) 1162–1174.
14. PinskyBA, KungC, ShokatKM, BigginsS (2006) The Ipl1-Aurora protein kinase activates the spindle checkpoint by creating unattached kinetochores. Nat Cell Biol 8 (1) 78–83.
15. PinskyBA, BigginsS (2005) The spindle checkpoint: tension versus attachment. Trends Cell Biol 15 (9) 486–493.
16. EarnshawWC, HeckMM (1985) Localization of topoisomerase II in mitotic chromosomes. J Cell Biol 100 (5) 1716–1725.
17. TavorminaPA, ComeMG, HudsonJR, MoYY, BeckWT, et al. (2002) Rapid exchange of mammalian topoisomerase II alpha at kinetochores and chromosome arms in mitosis. J Cell Biol 158 (1) 23–29.
18. SchuelerMG, SullivanBA (2006) Structural and functional dynamics of human centromeric chromatin. Annu Rev Genomics Hum Genet 7: 301–313.
19. OsheroffN, ZechiedrichEL, GaleKC (1991) Catalytic function of DNA topoisomerase II. Bioessays 13 (6) 269–273.
20. DeweeseJE, OsheroffMA, OsheroffN (2008) DNA Topology and Topoisomerases: Teaching a “Knotty” Subject. Biochem Mol Biol Educ 37 (1) 2–10.
21. WarsiTH, NavarroMS, BachantJ (2008) DNA topoisomerase II is a determinant of the tensile properties of yeast centromeric chromatin and the tension checkpoint. Mol Biol Cell 19 (10) 4421–4433.
22. VasACJ, AndrewsCA, Kirkland-MateskyK, ClarkeDJ (2007) In Vivo Analysis of Chromosome Condensation in Saccharomyces cerevisiae. Mol Biol Cell 18 (2) 557–568.
23. DohmenRJ, WuP, VarshavskyA (1994) Heat-inducible degron: a method for constructing temperature-sensitive mutants. Science 263: 1273–1276.
24. Furniss K, Vas AC, Lane A, Clarke DJ (2009) Assaying topoisomerase II checkpoints in yeast. In: Clarke DJ, editor. DNA Topoisomerases. New York: Humana Press.
25. BaxterJ, DiffleyJF (2008) Topoisomerase II inactivation prevents the completion of DNA replication in budding yeast. Mol Cell 30 (6) 790–802.
26. BairdCL, HarkinsTT, MorrisSK, LindsleyJE (1999) Topoisomerase II drives DNA transport by hydrolyzing one ATP. Proc Natl Acad Sci U S A 96 (24) 13685–13690.
27. DongKC, BergerJM (2007) Structural basis for gate-DNA recognition and bending by type IIA topoisomerases. Nature 450 (7173) 1201–1205.
28. LindsleyJE, WangJC (1991) Proteolysis patterns of epitopically labeled yeast DNA topoisomerase II suggest an allosteric transition in the enzyme induced by ATP binding. Proc Natl Acad Sci U S A 88 (23) 10485–10489.
29. LiuQ, WangJC (1998) Identification of active site residues in the “GyrA” half of yeast DNA topoisomerase II. J Biol Chem 273 (32) 20252–20260.
30. LiuQ, WangJC (1999) Similarity in the catalysis of DNA breakage and rejoining by type IA and IIA DNA topoisomerases. Proc Natl Acad Sci U S A 96 (3) 881–886.
31. LiuYX, HsiungY, JannatipourM, YehY, NitissJL (1994) Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide. Cancer Res 54 (11) 2943–2951.
32. WassermanRA, WangJC (1994) Mechanistic studies of amsacrine-resistant derivatives of DNA topoisomerase II. Implications in resistance to multiple antitumor drugs targeting the enzyme. J Biol Chem 269 (33) 20943–20951.
33. JensenS, RedwoodCS, JenkinsJR, AndersenAH, HicksonID (1996) Human DNA topoisomerases II alpha and II beta can functionally substitute for yeast TOP2 in chromosome segregation and recombination. Mol Gen Genet 252 (1–2) 79–86.
34. TavorminaPA, BurkeDJ (2000) Cell cycle arrest in cdc20 mutants of Saccharomyces cerevisiae is independent of Ndc10p and kinetochore function but requires a subset of spindle checkpoint genes. Genetics 148 (4) 1701–1713.
35. IoukT, KerscherO, ScottRJ, BasraiMA, WozniakRW (2002) The yeast nuclear pore complex functionally interacts with components of the spindle assembly checkpoint. J Cell Biol 159 (5) 807–819.
36. BowerJJ, ZhouY, ZhouT, SimpsonDA, ArlanderSJ, et al. (2010) Revised genetic requirements for the decatenation G2 checkpoint: the role of ATM. Cell Cycle 9 (8) 1617–28.
37. ClarkeDJ, VasAC, AndrewsCA, Díaz-MartínezLA, Giménez-AbiánJF (2006) Topoisomerase II checkpoints: universal mechanisms that regulate mitosis. Cell Cycle 5 (17) 1925–8.
38. VagnarelliP, MorrisonC, DodsonH, SonodaE, TakedaS, et al. (2004) Analysis of Scc1-deficient cells defines a key metaphase role of vertebrate cohesin in linking sister kinetochores. EMBO Rep 5 (2) 167–71.
39. Burke D (2000) Methods in yeast genetics: Cold Spring Harbor Laboratory Press.
40. LiuH, NaismithJH (2008) An efficient one-step site-directed deletion, insertion, single and multiple-site plasmid mutagenesis protocol. BMC Biotechnol 8: 91.
41. StraightAF, MarshallWF, SedatJW, MurrayAW (1997) Mitosis in living budding yeast: anaphase A but no metaphase plate. Science 277 (5325) 574–578.
42. SelmeckiA, ForcheA, BermanJ (2006) Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 313: 367–370.
43. Holm, StearnsT, BotsteinD (1989) DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage. Mol Cell Biol 9 (1) 159–168.
44. ElseaSH, HsiungY, NitissJL, OsheroffN (1995) A Yeast Type II Topoisomerase Selected for Resistance to Quinolones. J Biol Chem 270: 1913–1920.
45. McClendonAK, RodriquezAC, OsheroffN (2005) Human Topoisomerase IIα Rapidly Relaxes Positively Supercoiled DNA. J Biol Chem 280: 39337–39345.
Štítky
Genetika Reprodukční medicínaČlánek vyšel v časopise
PLOS Genetics
2013 Číslo 10
- Management pacientů s MPN a neobvyklou kombinací genových přestaveb – systematický přehled a kazuistiky
- Management péče o pacientku s karcinomem ovaria a neočekávanou mutací CDH1 – kazuistika
- Primární hyperoxalurie – aktuální možnosti diagnostiky a léčby
- Vliv kvality morfologie spermií na úspěšnost intrauterinní inseminace
- Akutní intermitentní porfyrie
Nejčtenější v tomto čísle
- Dominant Mutations in Identify the Mlh1-Pms1 Endonuclease Active Site and an Exonuclease 1-Independent Mismatch Repair Pathway
- Eleven Candidate Susceptibility Genes for Common Familial Colorectal Cancer
- The Histone H3 K27 Methyltransferase KMT6 Regulates Development and Expression of Secondary Metabolite Gene Clusters
- A Mutation in the Gene in Labrador Retrievers with Hereditary Nasal Parakeratosis (HNPK) Provides Insights into the Epigenetics of Keratinocyte Differentiation